Clinical and pharmacological group: & nbsp

Antihypoxants and antioxidants

Included in the formulation
  • HYPOXEN®
    capsules inwards 
  • АТХ:

    N.07.X.X   Other drugs for the treatment of diseases of the nervous system

    Pharmacodynamics:

    The presence in the structure of the polyphenolic quinone component provides the antihypoxic effect of the drug (participation in the transfer of electrons in the respiratory chain). The drug prevents the development of free radical oxidation, promotes the destruction of peroxidation products. Increases the effectiveness of tissue respiration in hypoxic conditions, especially in organs with high levels of metabolism (brain, heart muscle, liver). Reduces oxygen consumption with significant physical exertion, improves tissue respiration, reduces mental and physical fatigue, facilitates the execution of labor-intensive physical operations. Optimizes the activity of mitochondria cells, reduces their oxygen consumption. It has powerful electron-acceptor properties, acts directly on the respiratory chain of the mitochondria. The presence of a thiosulfate group in the polymer structure provides anti-radical and antioxidant effects.

    Pharmacokinetics:

    The half-life is 15-30 minutes, excretion by the kidneys.

    Indications:

    Blood loss.

    Extreme / unfavorable working and living conditions, which are accompanied by oxygen deficiency (including highlands, conditions of the Arctic, underwater works).

    Mental and physical overstrain, operator activity and other heavy loads, accompanied by chronic fatigue and fatigue.

    In the complex therapy of stable angina pectoris (prevention of angina attacks), arterial hypertension, chronic heart failure of I and II functional class according to the NYHA classification.

    In the complex therapy of severe traumatic lesions, blood loss, extensive surgical interventions, respiratory diseases (bronchial asthma, pneumonia, obstructive bronchitis).

    IX.I10-I15.I10   Essential [primary] hypertension

    IX.I10-I15.I15   Secondary Hypertension

    IX.I20-I25.I20   Angina pectoris [angina pectoris]

    IX.I30-I52.I50.0   Congestive heart failure

    X.J10-J18.J18   Pneumonia without clarification of the pathogen

    X.J40-J47.J42   Chronic bronchitis, unspecified

    X.J40-J47.J44   Other chronic obstructive pulmonary disease

    X.J40-J47.J45   Asthma

    XVIII.R50-R69.R53   Malaise and fatigue

    XVIII.R50-R69.R57   Shock, not elsewhere classified

    XVIII.R50-R69.R58   Bleeding, not elsewhere classified

    XIX.T08-T14.T14.9   Injury, unspecified

    XIX.T20-T32.T30   Thermal and chemical burns, unspecified

    XVIII.R50-R69.R68.8   Other specified general symptoms and signs

    XIX.T79.T79.4   Traumatic shock

    XIX.T80-T88.T81.1   Shock during or after the procedure, not elsewhere classified

    XXI.Z70-Z76.Z73.0   Overwork

    XXI.Z70-Z76.Z73.2   Insufficient rest and relaxation

    XXI.Z70-Z76.Z73.6   Limitations of activities caused by a decrease or loss of ability to work

    Contraindications:
    • Hypersensitivity
    • Violation of cerebral circulation (hemorrhagic stroke)
    • Pregnancy and lactation
    • Cachexia, a significant weakening of the body.
    Carefully:

    No data.

    Pregnancy and lactation:

    Category by FDA not determined. Do not use when pregnant and breast-feeding.

    Dosing and Administration:

    The duration of treatment is determined by the attending physician.

    Inside before or during meals, with a small amount of liquid; adults 0.5-1 g 3 times a day, children 0.25 g 3 times a day; the duration of the course is 3-14 days.

    Intravenously in the form of infusions (the contents of the ampoule ex tempore are dissolved in 200-400 ml of physiological solution or 5% glucose solution) at a rate of 40-60 drops per minute 1-3 times a day for 3-5 days.

    Side effects:

    Allergic reactions (erythema, pruritus, hypotension).

    Overdose:

    Symptoms: dry mouth, boli in the abdomen, nausea, vomiting, oppression of the respiratory center, drowsiness.

    Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

    Interaction:

    No data.

    Special instructions:

    At the time of taking the drug, blood pressure monitoring is necessary.

    It is necessary to avoid rapid intravenous administration (hypotension may develop; HELL should immediately stop the infusion and begin the introduction of mezaton, dobutamine or other pressor agents).

    Impact on the ability to drive vehicles and manage mechanisms not found.

    Instructions
    Up